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Background: Most pediatric lipodystrophy data come from high-income/
middle-income countries, but most HIV-infected children live in sub-Saha-
ran Africa, where lipodystrophy studies have predominantly investigated 
stavudine-based regimens.
Methods: Three years after antiretroviral therapy (ART) initiation, body 
circumferences and skinfold thicknesses were measured (n = 590), and 
fasted lipid profile assayed (n = 325), in children from 2 ARROW trial cen-
tres in Uganda/Zimbabwe. Analyses compared randomization to long-term 
versus short-term versus no zidovudine from ART initiation [unadjusted; 
latter 2 groups receiving abacavir+lamivudine+non-nucleoside-reverse-
transciptase-inhibitor (nNRTI) long-term], and nonrandomized (con-
founder-adjusted) receipt of nevirapine versus efavirenz.
Results: Body circumferences and skinfold thicknesses were similar regard-
less of zidovudine exposure (P > 0.1), except for subscapular and supra-iliac 
skinfolds-for-age which were greater with long-term zidovudine (0.006 < 
P < 0.047). Circumferences/skinfolds were also similar with efavirenz and 
nevirapine (adjusted P > 0.09; 0.02 < P < 0.03 for waist/waist-hip-ratio). 
Total and high-density lipoprotein (HDL)-cholesterol, HDL/triglyceride-
ratio (P < 0.0001) and triglycerides (P = 0.01) were lower with long-term 
zidovudine. Low-density lipoprotein (LDL)-cholesterol was higher with 
efavirenz than nevirapine (P < 0.001). Most lipids remained within normal 
ranges (75% cholesterol, 85% LDL and 100% triglycerides) but more on 
long-term zidovudine (3 NRTI) had abnormal HDL-cholesterol (88% vs. 
40% short/no-zidovudine, P < 0.0001). Only 8/579(1.4%) children had clini-
cal fat wasting (5 grade 1; 3 grade 2); 2(0.3%) had grade 1 fat accumulation.
Conclusions: Long-term zidovudine-based ART is associated with simi-
lar body circumferences and skinfold thicknesses to abacavir-based ART, 
with low rates of lipid abnormalities and clinical lipodystrophy, providing 
reassurance where national programs now recommend long-term zidovu-
dine. Efavirenz and nevirapine were also similar; however, the higher LDL 
observed with efavirenz and lower HDL observed with zidovudine suggests 
that zidovudine+lamivudine+efavirenz should be investigated in future.
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(Pediatr Infect Dis J 2015;34:e23–e31)
The lipodystrophy syndrome, which includes central lipohypertro-phy, lipoatrophy of extremities, face and buttocks, and metabolic 
abnormalities, has been reported among naive and experienced HIV-
infected children on antiretroviral therapy (ART) in resource-rich 
and resource-limited settings.1–14 Observed risk factors in children 
include: use of stavudine and protease inhibitors; advanced HIV dis-
ease, high viral loads and low CD4; duration of HIV infection/older 
age; puberty; female gender; white ethnicity; high body mass index 
(BMI); and rapid immunological recovery post-ART.1,2,4,6,8,13–18
Much lipodystrophy data in children come from middle-
income/high-income countries, whereas >90% of HIV-infected 
children live in sub-Saharan Africa19 where underlying malnutri-
tion, micronutrient deficiencies, co-infections and advanced HIV 
disease are more prevalent. Lipodystrophy studies specifically 
among sub-Sarahan African children are thus needed. Two recent 
cross-sectional studies in Uganda and Tanzania reported clinically 
ascertained lipodystrophy in 27–34% children, although most 
cases were mild13,14; a third cross-sectional randomized comparison 
of nevirapine versus lopinavir-containing ART reported lipodystro-
phy in 8.4%.20 Importantly, most13,14 or all20 children had substantial 
stavudine exposure, which was associated with lipodystrophy,13,14 
similar to a cross-sectional study of skinfolds/circumferences in 
Ugandan/Zambian children.21
Many African ART programs are moving away from stavu-
dine-containing regimens in children, as in adults.22–24 Children now 
predominantly receive zidovudine-containing regimens, as concerns 
remain about tenofovir’s impact on bone metabolism and renal func-
tion,25,26 and abacavir remains expensive.27 Like stavudine, zidovu-
dine is a thymidine-analog nucleoside reverse transcriptase inhibitor 
(NRTI) so could potentially lead to lipodystrophy, albeit at lower 
rates.13,14,28 Non-nucleoside reverse transcriptase inhibitors (NNR-
TIs) have also been associated with lipodystrophy,1 with, if any-
thing, higher rates in those receiving nevirapine versus efavirenz.29,30
Here, we investigate the contribution of zidovudine and efa-
virenz/nevirapine to body circumferences, skinfold thicknesses, 
metabolic parameters and clinically determined lipodystrophy, in 
randomized (zidovudine) and nonrandomized (efavirenz/nevirap-
ine) comparisons 3 years after ART initiation in the ARROW trial.31
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METHODS
In ARROW (ISRCTN24791884), previously untreated Ugan-
dan/Zimbabwean children/adolescents age 3 months to 17 years, 
eligible for ART using World Health Organization (WHO) 2006 cri-
teria,32 were randomized 1:1 to clinically driven monitoring versus 
laboratory plus clinical monitoring for toxicity (hematology/bio-
chemistry) and efficacy (CD4). Children were also randomized 1:1:1 
in a factorial design to open-label lamivudine+abacavir+NNRTI 
continuously (Arm-A, no zidovudine); induction-maintenance with 
4-drug lamivudine+abacavir+NNRTI+zidovudine for 36 weeks, 
followed by lamivudine+abacavir+NNRTI (Arm-B; short-term 
zidovudine) or lamivudine+abacavir+zidovudine (Arm-C; long-
term zidovudine). The NNRTI (nevirapine/efavirenz) was chosen 
by clinicians according to local availability (varying by country) 
and age. Caregivers gave written consent; older children (8–17 
years) aware of their HIV status also gave assent or consent follow-
ing national guidelines. ARROW was approved by Research Eth-
ics Committees in Uganda, Zimbabwe and the UK. Children were 
recruited from 3 centers in Uganda [Joint Clinical Research Cen-
tre, Kampala; Baylor-Uganda, Mulago and MRC/UVRI Uganda 
Research Unit on AIDS, Entebbe], and 1 in Zimbabwe (University 
of Zimbabwe, Harare).
Two centers (Joint Clinical Research Centre and Harare) 
undertook a metabolic sub-study with a separate protocol 
(approved by Research Ethics Committees in both countries) and 
consent/assent as above. The primary sub-study cross-sectional 
objective was to compare children randomized to long-term zido-
vudine-containing ART with short-term zidovudine-containing or 
nonzidovudine-containing ART in terms of prevalence of the lipo-
dystrophy syndrome 3 years after ART initiation. At the scheduled 
visit 3 years (156 weeks) after ART initiation, questionnaires were 
completed by the caregiver and physician (same for all visits); body 
circumferences (waist, hip, mid-thigh, mid-upper-arm) and skin-
fold thicknesses (triceps, subscapular, supra-iliac, mid-thigh) were 
measured by 1 nurse at each site; and blood taken (no intake other 
than water for 6 hours prior, wherever possible) for total cholesterol 
and triglycerides in real-time, and in batched retrospective analysis 
lipid fractions [directly assayed high-density lipoprotein (HDL) and 
low-density lipoprotein (LDL)], glucose, total protein and albumin 
(Harare only). For circumferences and skinfold thicknesses, proce-
dures were standardized with prespecified positions for 3 repeated 
measurements to reduce interoperator and intervisit variability, fol-
lowing the Anthropometric Standardization Manual,33 using T/W 
callipers (Holtain limited, Crymych, UK) for skin-fold thicknesses. 
Waist and hip circumferences were also collected every 4–6 weeks 
in all ARROW children.
Analysis
Analysis used the mean of the 3 measurements at the visit 
nearest to 3-years from ART initiation within ±24 weeks. As no 
African reference data were available, Z-scores were determined 
using Dutch reference values and analyses focused on differences 
between groups.34,35 No reference data was available for mid-thigh 
skinfold thickness. Weight-for-age and height-for-age were calcu-
lated using UK reference ranges.36 Total and LDL cholesterol, tri-
glycerides, glucose and albumin were considered abnormal accord-
ing to37; HDL was considered abnormal if <1.04 mmol/L.38
Randomized ART strategy groups were compared using χ2 
or exact tests for categorical factors and one-way analysis of vari-
ance for continuous values. Randomization means these unadjusted 
comparisons are unbiased in expectation; there was no evidence 
of chance imbalances in pre-ART factors across groups (P > 0.3). 
A nonrandomized comparison of nevirapine versus efavirenz was 
also undertaken in children ≥3 years at ART initiation (no efavirenz 
dose for <3 years at the time), adjusted for potential confounders: 
age at 3-year measurement, sex, center, ART-strategy randomiza-
tion, calendar year of ART initiation, pre-ART CD4% and any 
change in NNRTI from initiation. Absolute Z-scores for waist/hip 
circumferences measured in all children (n = 1206) were also com-
pared using generalized estimating equations (normal distribution, 
independent working correlation, closest measurement to 12-week 
timepoints in equally spaced windows) (models for change from 
baseline in the subset enrolled from May 2008 when measurements 
started were similar, data not shown).
Predictors of the sum of the skinfolds were considered using 
normal linear regression with backward elimination (exit P = 0.05) 
on the factors above plus pre-ART WHO stage; monitoring rand-
omization; and CD4%, height and BMI for age at ART initiation, 
3-years and change during the first 6 months on ART. ART-strategy 
randomization was included regardless of significance. Weight-for-
age was not considered as it was strongly associated with height-
for-age (Spearman correlation ≥0.74). Only 56% children had HIV 
viral load assayed at 3 years, so this was not considered. Nonlinear-
ity in effects of continuous predictors was explored using natural 
cubic splines (3 knots at 10th, 50th and 90th centiles). Children 
were grouped by body circumference/skinfold Z-scores (7 meas-
urements/child) using complete-linkage cluster analysis. All analy-
ses were performed using Stata 12.1 (StataCorp). All P-values are 
two-sided. No adjustment was made a priori for multiple testing.
RESULTS
Seven hundred and eighteen ARROW children were 
enrolled (March 2007–October 2008) at metabolic sub-study cent-
ers; 686 were alive in follow-up 3 years later (27 deaths and 5 lost). 
Five hundred and ninety-two (86.3%) had 3-year measurements 
(remainder had measurements outside the window, or did not con-
sent/were not approached, for example, if older children were unac-
companied). Two previously pregnant participants were excluded, 
leaving 590 in analyses, age median 9 years (range, 3–19).
Children had initiated ART (23.9% aged <3) with advanced 
disease, but recovered well (Table 1). Children randomized to Arms 
A, B and C had spent 3.5%, 24.8% and 96.5% child-time on zido-
vudine-containing ART, respectively, by the 3-year measurement. 
Arm A/B children >3 years at ART initiation and on nevirapine/
efavirenz at 3 years had spent 99.1% and 98.1% child-time on 
nevirapine or efavirenz, respectively. At ART initiation and 3 years 
subsequently, only 5 and 2 children had BMI-for-age Z-score >2 
(maximum BMI 23 and 19), respectively.
Anthropometric Measurements
After 3 years on ART, few children had measurements ≤5th 
percentile of Dutch reference ranges for central measures [0/576 
(0.0%) waist circumference; 34/578 (5.9%) hip; 33/577 (5.7%) 
subscapular and 16/578 (2.8%) supra-iliac skinfold thickness]. Sub-
stantial proportions were ≤5th percentile for extremities [402/576 
(69.8%) mid-thigh and 190/579 (32.8%) mid-upper arm circumfer-
ence; 144/578 (24.9%) triceps skinfold thickness]. However, pro-
portions were similar in children receiving long-term zidovudine 
(71.2%, 32.8%, 22.1%, respectively) and not receiving long-term 
zidovudine (ie, receiving long-term abacavir; 69.1%, 32.8%, 26.3% 
respectively; P > 0.3); <1% measurements were ≥95th percentile 
on any measure.
There were no significant differences by randomized ART-
strategy, or long-term zidovudine (Arm-C) versus no or short-term 
zidovudine combined (Arms A/B), for any body circumference (P > 0.5; 
Z-score P > 0.6), waist-hip ratio (P > 0.14; Z-score, P > 0.6), or 
waist-arm ratio (P > 0.6) (Table 1). There were also no significant 
differences in skinfold thicknesses or triceps skinfold Z-score 
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(P > 0.1), but subscapular and supra-iliac skinfold Z-scores were 
slightly but significantly higher in those receiving zidovudine long-
term (Arm-A/B vs. C P = 0.006, P = 0.02, respectively).
There were also no significant differences in skinfold thick-
ness, hip, mid-thigh and mid-upper arm body circumferences and 
their Z-scores, or waist-arm ratio, between efavirenz-containing 
and nevirapine-containing regimens (adjusted P > 0.09; Table 1), 
but waist circumference (and Z-score) and waist-hip ratio were 
slightly but significantly lower in those receiving efavirenz in the 
metabolic substudy (P = 0.04, 0.03 and 0.02, respectively; waist-
hip ratio Z-score marginally lower, P = 0.06). In all 1206 children, 
there were no differences in waist and hip circumference Z-scores 
between children receiving efavirenz or nevirapine in the long-term 
(Figure 1). Hip circumference was slightly but significantly higher 
in those receiving efavirenz at ART initiation and then over the 
first 60 weeks on ART, leading to a significant difference overall 
(P = 0.01) (driven by greater nevirapine use in younger children). 
However, there was no evidence of difference overall in waist cir-
cumference or waist-hip ratio (P = 0.13 and 0.12, respectively), and 
no differences in waist/hip circumferences or their ratio by rand-
omized ART-strategy (P > 0.2).
Cluster analysis identified 4 main groups of children: 
those relatively large-for-age on all measurements (relatively high 
Z-scores) but with higher body circumferences than skinfold thick-
nesses (ie, very lean, n = 103, 29.1% Arm-C); relatively large-for-
age on all measurements but with higher skinfold thicknesses than 
body circumferences (plump; n = 70, 42.9% Arm-C); intermediate-
for-age on all measurements (n = 337, 33.2% Arm-C) or low-for-
age on all measurements, although typically with even lower body 
circumferences than skinfold thicknesses (n = 54, 25.9% Arm-C). 
Proportions in Arm-C did not differ significantly between the 4 
groups (Arm-C vs. A/B P = 0.17).
TABLE 1. Characteristics at ART Initiation and at 3-year Measurement
Total  
N = 590
JCRC  
N = 265
Harare  
N = 325
Male 300 (50.8%) 129 (48.7%) 171 (52.6%)
At ART initiation
  Age <3 years 141 (23.9%) 77 (29.1%) 64 (19.7%)
  CD4: median (IQR) 318 (168, 583) 362 (181, 636) 305 (160, 540)
  CD4%: median (IQR) 12 (7, 16) 14 (8, 18) 11 (7, 15)
  Weight-for-age Z-score: median (IQR) −2.1 (−3.2, −1.2) −1.7 (−2.8, −1.0) −2.5 (−3.6, −1.5)
  Height-for-age Z-score: median (IQR) −2.4 (−3.3, −1.6) −2.0 (−2.9, −1.1) −2.8 (−3.5, −1.9)
  BMI-for-age Z-score: median (IQR) −0.8 (−1.6, 0.0) −0.7 (−1.5, 0.0) −0.8 (−1.8, 0.0)
  WHO stage
   1/2 174 (29.5%) 135 (50.9%) 39 (12.0%)
   3 347 (58.8%) 97 (36.6%) 250 (76.9%)
   4 69 (11.7%) 33 (12.5%) 36 (11.1%)
  Randomized treatment strategy
   Arm A (3TC/ABC/NNRTI throughout) 195 (33.1%) 89 (33.6%) 106 (32.6%)
   Arm B (36 weeks ZDV) 201 (34.1%) 90 (34.0%) 111 (34.2%)
   Arm C (long-term ZDV) 194 (32.9%) 86 (32.5%) 108 (33.2%)
  Allocated monitoring strategy
   Laboratory and clinical monitoring (routine CD4 monitoring) 290 (49.2%) 130 (49.1%) 160 (49.2%)
   Clinically driven monitoring (no CD4 monitoring) 300 (50.8%) 135 (50.9%) 165 (50.8%)
Three-year measurement
  Years on ART: median (IQR) 3.0 (3.0, 3.0) 3.0 (3.0, 3.0) 3.0 (2.8, 3.1)
  Age: median (IQR) 9.7 (6.0, 12.6) 8.9 (5.6, 12.4) 10.6 (6.5, 12.7)
  ART combination
   3TC+ABC+NVP 210 (35.6%) 56 (21.1%) 154 (47.4%)
   3TC+ABC+EFV 177 (30.0%) 119 (44.9%) 58 (17.8%)
   3TC+ABC+ZDV 190 (32.2%) 88 (33.2%) 102 (31.4%)
   Other NVP-containing first-line 1 (0.2%) 0 (0.0%) 1 (0.3%)
   None* 1 (0.2%) 1 (0.4%) 0 (0.0%)
   2NRTI+ALV 10 (1.7%) 1 (0.4%) 9 (2.8%)
   EFV+ALV 1 (0.2%) 0 (0.0%) 1 (0.3%)
  Tanner stage
   1 109 (18.5%) 30 (11.3%) 79 (24.3%)
   2 76 (12.9%) 32 (12.1%) 44 (13.5%)
   3 49 (8.3%) 19 (7.2%) 30 (9.2%)
   4-5 48 (8.1%) 29 (10.9%) 19 (5.8%)
   >=10 years but not staged 2 (0.3%) 1 (0.4%) 1 (0.3%)
   <10 years at 3-year measurement 306 (51.9%) 154 (58.1%) 152 (46.8%)
  CD4: median (IQR) 780 (543, 1092) 850 (575, 1209) 750 (533, 1019)
  CD4% >10% above pre-ART 525 (89.0%) 226 (85.3%) 299 (92.0%)
  Weight-for-age Z-score: median (IQR) −1.3 (−2.1, −0.6) −1.2 (−1.9, −0.5) −1.5 (−2.1, −0.8)
  Height-for-age Z-score: median (IQR) −1.7 (−2.3, −1.0) −1.3 (−2.0, −0.6) −1.9 (−2.5, −1.3)
  BMI-for-age Z-score: median (IQR) −0.5 (−1.1, 0.1) −0.5 (−1.1, 0.0) −0.5 (−1.1, 0.1)
  HIV viral load
   No value available 240 (40.7%) 98 (37.0%) 142 (43.7%)
   <80 (% of those with values) 267 (76.3%) 125 (74.9%) 142 (77.6%)
   80–399 (% of those with values) 21 (6.0%) 11 (6.6%) 10 (5.5%)
   400–- (% of those with values) 62 (17.7%) 31 (18.6%) 31 (16.9%)
*Voluntary decision since week 133
ABC indicates abacavir; 3TC, lamivudine; ZDV, zidovudine; NVP, nevirapine; EFV, efavirenz; ALV, lopinavir/ritonavir (Aluvia); ART, antiretroviral therapy; IQR, interquartile 
range.
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At 3 years, the sum of the 4 skinfolds was significantly 
(P < 0.05) and independently higher in children receiving long-
term zidovudine (Arm-C) versus no (Arm-A) or short-term (Arm-
B) zidovudine [Arm-C vs. A/B adjusted difference +0.49 mm (95% 
confidence interval (CI), +0.02, +0.97); P = 0.04], girls, Ugandan 
children (vs. Zimbabwean) and those with higher current BMI-for-
age (Table 2). In children with pre-ART height-for-age Z-score ≥3, 
sum-of-skinfolds 3 years after ART initiation increased signifi-
cantly with higher pre-ART height-for-age (P < 0.0001); in children 
with height-for-age ≤3 pre-ART, there was no evidence of associa-
tion (P = 0.44). Current height-for-age had no independent effect 
(P = 0.29) after adjustment for pre-ART height-for-age (Spear-
man correlation = 0.73). Under 10 years, there was only weak 
association between age and sum-of-skinfolds (P = 0.07); over 
10 years, sum-of-skinfolds increased significantly with older age 
(P < 0.0001), likely reflecting pubertal effects.
Biochemistry
Biochemistry was available for 319 children, 256 (80.3%) 
known to have fasted for >6 hours (75.2% Arm-A, 78.0% Arm-B, 
87.6% Arm-C; P = 0.06). Mean total and HDL cholesterol were signif-
icantly lower with long-term zidovudine (Arm-C, HDL 0.8 mmol/L) 
compared to no (Arm-A, 1.2 mmol/L) or short-term zidovudine 
(Arm-B, 1.2 mmol/L) (one-way analysis of variance P < 0.0001), 
with LDL similar across ART-strategy (Table 3). Mean triglycerides 
were 0.8 mmol/L, with no significant differences by ART-strategy; 
consequently the HDL/triglyceride ratio was significantly lower 
with long-term zidovudine (Arm-C, 1.4) than no (Arm-A, 2.1) or 
short-term zidovudine (Arm-B, 2.4) (P < 0.0001). Similarly, the 
total cholesterol/triglyceride ratio was significantly lower in Arm-C 
(5.6) than Arm-A (7.1) or Arm-B (7.5) (P = 0.01). Eighty-one 
children (25.4%) had elevated total cholesterol, fewer in Arm-C 
(P = 0.008; Table 4); 39/81 had a family history of hypertension and 
13 of stroke. However, 174 (55.1%) children still had abnormally 
low HDL, more in Arm-C (P < 0.0001). Mean glucose, total protein 
and albumin were 4.74 mmol/L, 76.9 g/L and 40.2 g/L, respectively, 
with no significant differences between long-term, short-term or no 
zidovudine.
LDL cholesterol was significantly higher in those tak-
ing efavirenz-containing versus nevirapine-containing regimens 
[adjusted difference +0.44 mmol/L (95% CI, +0.18, +0.70); 
P = 0.001]; HDL was nonsignificantly lower [−0.12 mmol/L (95% 
CI, −0.27, +0.04)], as was albumin [−1.46 g/L (95% CI, −3.00, 
+0.08)]. There were no other significant biochemical differences 
between efavirenz-containing and nevirapine-containing groups.
Although there was weak correlation between total cho-
lesterol and triglycerides (Spearman correlation = 0.30), pairwise 
correlations between lipid fractions, triglycerides and the other 
biochemical measurements were low (Spearman correlation <0.3). 
Biochemical and anthropometric measurements were uncorrelated 
(Spearman rho <0.2).
Physician Assessment of Changes in Body Shape 
Since ART Initiation
Any fat loss since ART initiation was reported in only 7/419 
children (1.7%) (all mild-moderate), 4 also with more visible veins 
reported (not reported in any other children). Five of the 7 chil-
dren reported to have any fat loss were also classified as having 
clinical signs/symptoms of abnormal fat wasting (all Ugandan); the 
other 2 children (Zimbabwean) were not. A further 3 children were 
also classified as having clinical signs/symptoms of abnormal fat 
wasting (changes in body shape data were missing). Hence in total 
8/579 children (1.4%) had clinical signs/symptoms of fat wast-
ing (Arm-A: 3/188; Arm-B: 3/198; Arm-C: 2/193), 5 grade 1 (2 
Arm-A,1 Arm-B, 2 Arm-C) and the remainder grade 2. Of the 6 in 
Arm A/B (receiving abacavir long-term), 4 had received efavirenz, 
1 nevirapine and 1 had substituted efavirenz with nevirapine for 
lipodystrophy.
Any fat gain since ART initiation was reported in 174/419 
children (41.5%), only 1 severe (face and buttocks). Only 2 chil-
dren had clinical signs/symptoms of abnormal fat accumulation 
reported by clinicians, both grade 1 (1 Arm-A, 1 Arm-C; both had 
received efavirenz, although only to week 36 in Arm-C).
Among all 1206 children/adolescents, there were only 8 
ART-modifications for lipoatrophy/lipodystrophy (two <3 years on 
ART and 3 in the children above with clinical signs/symptoms of 
abnormal fat wasting). Efavirenz was substituted with nevirapine 
in 2 children for gynecomastia (1 Arm-A, 1 Arm-B) and 3 for lipo-
dystrophy (1 Arm-A, 2 Arm-B). Two children substituted zidovu-
dine with nevirapine for lipoatrophy in Arm-C; and another Arm-C 
child, already off zidovudine because of anemia, substituted stavu-
dine with tenofovir.
DISCUSSION
Detailed investigation of a large, nonblinded group of chil-
dren randomized to first-line ART containing long-term, short-
term or no zidovudine, found no increased risk of lipoatrophy/
p=0.01 unadjusted 0.13 adjusted
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body shape changes with long-term zidovudine use using WHO 
weight-band ART doses through 3 years, and generally similar 
impact of zidovudine+lamivudine and abacavir+lamivudine NRTI 
backbones. Along with reassuring data on low incidence of excess 
anemia with zidovudine already reported,31 these similar lipodys-
trophy rates provide important reassurance where first-line pedi-
atric regimens have changed from stavudine to zidovudine, as 
there have been concerns that zidovudine (also a thymidine ana-
logue) could still cause lipoatrophy/lipodystrophy, albeit at lower 
rates than stavudine. The substantially lower potential for lipoat-
rophy from zidovudine is supported by reversal of signs in Thai 
children switched from stavudine to zidovudine-containing regi-
mens.39 Efficacy is also important when considering the relative 
merits of different pediatric ART regimens. However, ARROW 
children receiving long-term zidovudine were all on triple NRTI 
maintenance regimens. While lipoatrophy/body shape changes 
on this regimen are plausibly generalizable to standard long-
term zidovudine+lamivudine+NNRTI regimens, poorer viro-
logic response with 3NRTI regimens over the longer-term31 is 
unlikely to reflect responses on zidovudine+lamivudine+NNRTI. 
In children, abacavir+lamivudine was virologically superior 
to zidovudine+lamivudine in a randomized comparison over 5 
years,40,41 but inferior to stavudine+lamivudine in a South African 
cohort study.42 In adults, a meta-analysis of 9 randomized trials 
(n = 2159) concluded there was no virologic difference between 
zidovudine-containing and stavudine-containing regimens.43 The 
relative virologic efficacy of stavudine-containing, zidovudine-
containing and abacavir-containing NRTI backbones in children is 
therefore currently unclear, but will be addressed by the CHAPAS-3 
trial (www.chapas3trial.org).
Overall, lipodystrophy rates among ARROW children were 
low compared to previous studies in African ART-treated chil-
dren,13,14,20 possibly because stavudine (as a first-line substitution) 
and protease inhibitor (as second-line) use was minimal. Alterna-
tively, observed rates may highlight challenges in applying sub-
jective lipodystrophy definitions when children’s body shapes are 
changing, given low clinical suspicion without stavudine/protease 
inhibitors. As lipodystrophy has rarely been assessed blinded to 
ART (nor did we do this), it is impossible to exclude the potential 
for ascertainment bias, although this is less likely with skinfold and 
body circumference measurements. Another study limitation is that 
we did not assess anthropometry or metabolic parameters pre-ART, 
so we could only compare children cross-sectionally after 3 years 
on ART (albeit based on randomized groups), rather than com-
paring changes from ART initiation. The relatively low pre-ART 
weight-for-age, which would be expected to be associated with low 
cholesterol and raised triglycerides, might have shifted the balance 
between harmful and beneficial effects of ART on anthropometric/
metabolic parameters toward benefit in the short-term to medium-
term.44
We found children receiving long-term zidovudine had sig-
nificantly lower HDL and total cholesterol (likely driven by lower 
HDL) than those receiving NNRTI-based ART long-term, lead-
ing to substantially lower HDL/triglyceride and total cholesterol/
triglyceride ratios. Lower HDL could reflect a greater tendency to 
dyslipidemia with long-term zidovudine, or could be because chil-
dren receiving long-term zidovudine were all on 3 NRTI mainte-
nance regimens with no NNRTI. How potentially greater risk from 
low HDL balances against lower risk from reduced total choles-
terol/triglyceride ratio is unclear, but an abnormal HDL/triglyc-
eride ratio has been strongly associated with coronary disease in 
adults, suggesting atherogenic effects.45 We also found significantly 
higher LDL, and a trend toward lower HDL cholesterol, in children 
receiving efavirenz versus nevirapine. Increases in nonfasting HDL 
cholesterol were lower among adults receiving efavirenz compared 
with nevirapine,46 and in a large Tanzanian cohort.44 Although these 
studies found no significant differences in calculated (not meas-
ured) LDL, 1 randomized trial reported significant decreases in 
LDL cholesterol following switch from efavirenz-containing to 
nevirapine-containing ART in adults with dyslipidemia.47 No child 
in this substudy was receiving zidovudine+lamivudine+efavirenz 
(used very rarely in ARROW as a toxicity substitution), but, 
together, these results suggest that this combination could more 
likely lead to disturbed lipid profiles over the longer-term. As this 
regimen is commonly used globally, and is likely to become even 
more so given recent licensing of efavirenz in children <3 years48 
and suggestion of improved virologic suppression versus nevirap-
ine,49,50 this should be investigated in future studies. However, our 
findings show that such studies will need to directly measure HDL, 
and ideally also LDL.
Despite their statistical significance, most changes in lipids 
were still within the normal range. The only significant differ-
ence in graded toxicity was for total cholesterol, where 13.3% 
of those receiving long-term zidovudine had elevated values (all 
TABLE 2. Independent Predictors of the Sum of 4 Skinfold Measurements 3 Years After ART Initiation
Factor
Estimate (mm)  
(95% CI) P
Allocated treatment strategy, vs. Arm A (3TC/ABC/NNRTI)* 0.13
  Arm B (36 weeks ZDV) 0.1 (−1.1, 1.2) 0.87
  Arm C (long-term ZDV) 1.0 (−0.1, 2.1) 0.07
Male −3.8 (−4.7, −2.9) <0.0001
Height-for-age Z-score at ART initiation (per unit Z-score higher) <0.0001
  Z-score at ART initiation ≤ −3 −0.3 (−1.2, 0.5) 0.44
  Z-score at ART initiation > −3 1.1 (0.6, 1.7) <0.0001
BMI-for-age Z-score at 3-year measurement 2.6 (2.1, 3.1) <0.0001
Age at 3-year measurement (per year increase) <0.0001
  <10 years 0.24 (−0.02, 0.50) 0.07
  ≥10 years 1.5 (1.3, 1.8) <0.0001
Harare −3.4 (−4.4, −2.4) <0.0001
Reference category: Ugandan girl, aged 10, in Arm A (3TC/ABC/NNRTI); with height-for-age −2 at 
ART initiation and BMI-for-age −1 three years after ART initiation
28.6 (25.4, 31.8) <0.0001
* Arm-C versus A/B combined P = 0.04 [adjusted difference +0.49 mm (95% CI, 0.02, 0.97)].
ABC indicates abacavir, 3TC, lamivudine; ZDV, zidovudine.
Factors considered that were not included in the final model were pre-ART WHO stage, CD4% and BMI-for-age; 3-year CD4% and height-for-age; change in CD4%, height-for-
age and BMI-for-age during first 6 months on ART; monitoring randomization. ART strategy randomization was included regardless of statistical significance. Weight-for-age was 
strongly associated with height-for-age and therefore was not considered, nor was viral load as only 56% of children had a value available.
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receiving 3NRTI maintenance), compared with 31.3% receiv-
ing NNRTI without zidovudine long-term; and HDL cholesterol, 
where 86.4% and 39.9% had abnormally low values respectively. 
However, most abnormalities were low grade (1–2); with the 
abacavir+lamivudine+NNRTI/3 NRTI long-term regimens used, 
we found very few children had sufficiently severe lipid abnormali-
ties after 3 years on ART to consider switching or using lipid-lower-
ing therapy. The modest nature of the changes, their unclear clinical 
significance and uncertainty regarding the role of pharmacologic 
interventions, suggest there is little reason to regularly monitor for 
lipid toxicity, as for other biochemical toxicities,31 particularly in 
low-income settings. However, the impact over timescales longer 
than 3 years is unknown, although previous data in children sug-
gest that the most pronounced lipid changes occur during the first 
year on ART.51
The major limitation of our study is its cross-sectional 
design, a consequence of being setup after trial recruitment had 
ended. However, zidovudine comparisons are randomized, elimi-
nating 1 potential source of bias. Furthermore, those receiving 
long-term zidovudine were on a 3NRTI regimen, which is only 
recommended in WHO guidelines during tuberculosis treatment. 
Although nevirapine and efavirenz were not randomized, both 
drugs were used in substantial numbers in each center, based 
mainly on age and individual recruiting clinician preference. 
Another limitation is the lack of country-specific reference val-
ues, necessitating the use of Dutch reference data,34,35 also used in 
Black African children in the UK. This makes interpreting absolute 
Z-scores difficult. Interestingly, Ugandan/Zimbabwean children 
appeared relatively similar to Dutch children on central measures, 
but had substantially more muscular/leaner extremities. This 
could be because of nondrug-specific ART (or even HIV) effects 
in these children, or to higher values in uninfected normal Dutch 
than Ugandan/Zimbabwean children. The lack of evidence support-
ing associations between abacavir and lipoatrophy, the low rates 
of lipoatrophy reported by clinicians regardless of ART exposure, 
and the generally more active lifestyle of African children support 
the former explanation. However, differences in Z-scores between 
groups are likely far less affected than absolute values. We found 
little or no evidence of differences between groups of Ugandan/
Zimbabwean children in unadjusted and adjusted analyses, so using 
different reference values would have been unlikely to alter this. 
Direct LDL and HDL measurement in mostly fasted children was 1 
study advantage. However, metabolic assays were only performed 
in Zimbabwe, whereas most children with abnormal clinical signs/
symptoms of lipodystrophy were Ugandan, making comparisons of 
metabolic parameters between those with and without lipodystro-
phy impossible. Finally, we investigated a large number of different 
parameters; some results (eg, higher subscapular and supra-iliac 
skinfolds with long-term zidovudine) could therefore be false-pos-
itives from multiple testing.
In summary, we found no evidence that long-term zidovu-
dine was associated with greater rates of lipodystrophy, or more 
severe abnormalities in body circumferences/skinfold thicknesses, 
than abacavir+lamivudine-based regimens in a randomized com-
parison 3 years after ART initiation, with only relatively small dif-
ferences in HDL and total cholesterol. These findings suggest that 
both zidovudine and abacavir are similarly safe NRTI options with 
respect to lipodystrophy/lipoatrophy/lipid measurements, which is 
TABLE 4. Graded Toxicity in Cholesterol, Lipid Fractions, Triglycerides, Glucose and Albumin 3 
Years After ART Initiation
Arm A (no ZDV)  
N = 105
Arm B (36 weeks ZDV)  
N = 109
Arm C (long-term ZDV)  
N = 105
Total  
N = 319
Total cholesterol (mmol/L) P = 0.008
  Normal: <4.4 73 (69.5%) 74 (67.9%) 91 (86.7%) 238 (74.6%)
  Grade 1: 4.40-5.15 15 (14.3%) 21 (19.3%) 8 (7.6%) 44 (13.8%)
  Grade 2: 5.16-7.77 17 (16.2%) 13 (11.9%) 6 (5.7%) 36 (11.3%)
  Grade 3: >7.77 0 (0.0%) 1 (0.9%) 0 (0.0%) 1 (0.3%)
HDL cholesterol (mmol/L) P < 0.0001
  Normal: ≥1.04 55 (52.9%) 73 (67.0%) 14 (13.6%) 142 (44.9%)
  Abnormal: <1.04 49 (47.1%) 36 (33.0%) 89 (86.4%) 174 (55.1%)
  Missing 1 0 2 3
LDL cholesterol (mmol/L) P = 0.20
  Normal: <2.85 84 (80.8%) 94 (86.2%) 92 (87.6%) 270 (84.9%)
  Grade 1: 2.85-3.34 15 (14.4%) 7 (6.4%) 6 (5.7%) 28 (8.8%)
  Grade 2: 3.35-4.90 5 (4.8%) 8 (7.3%) 7 (6.7%) 20 (6.3%)
  Missing 1 0 0 1
Triglycerides (mmol/L) P = 1.00
  Normal: <5.65 105 (100.0%) 109 (100.0%) 103 (100.0%) 317 (100.0%)
  Missing 0 0 2 2
  Glucose (mmol/L) P = 0.18
  Low-grade 2:  2.22-3.06 1 (1.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%)
  Low-grade 1: 3.05-3.55 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
  Normal: 3.65-6.10 97 (93.2%) 107 (98.2%) 103 (99.0%) 307 (96.8%)
  High-grade 1: 6.11-6.94 3 (2.9%) 2 (1.8%) 1 (1.0%) 6 (1.9%)
  High-grade 2: 6.95-13.88 3 (2.9%) 0 (0.0%) 0 (0.0%) 3 (0.9%)
  Missing 1 0 1 2
Albumin (g/L) P = 0.68
  Normal: ≥35 99 (95.2%) 102 (93.6%) 100 (95.2%) 301 (94.7%)
  Grade 1: 30–<35 5 (4.8%) 5 (4.6%) 5 (4.8%) 15 (4.7%)
  Grade 2: 20–29 0 (0.0%) 2 (1.8%) 0 (0.0%) 2 (0.6%)
  Missing 1 0 0 1
ZDV indicates zidovudine.
Tests exclude missing observations. Total and LDL cholesterol, triglycerides, glucose and albumin were considered abnormal according to 
the Division of AIDS grading37; HDL was considered abnormal <1.04 mmol/L (40 mg/dL).38 Children with elevated total cholesterol were receiv-
ing lamivudine+abacavir+nevirapine (44 children), lamivudine+abacavir+efavirenz (21), lamivudine+abacavir+zidovudine (12), lopinavir/
ritonavir+zidovudine+didanosine (2), lopinavir/ritonavir+lamivudine+didanosine (1) and lopinavir/ritonavir+efavirenz (1).
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reassuring given the wholescale move toward these regimens across 
Africa and the necessity for these children to receive ART. We also 
found no, or relatively small, differences between efavirenz and 
nevirapine. While these are longer-term data than those published 
to date on zidovudine-based ART in resource-limited settings, they 
are still short-term in the context of lifelong ART; given the severe 
adverse consequences of lipodystrophy, particularly for adolescents, 
and its impact on adherence, longer-term studies will be important.
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